Pre- and peri-operative strategies are becoming standard for the management of localized gastro-esophageal cancer. For localized gastric/gastro-esophageal junction (GEJ) cancer there are conflicting data that a peri-operative approach with cisplatin-based chemotherapy improves survival, with the benefits seen in esophageal cancer likely less than a 5-10% incremental improvement. Further trends toward improvement in local control and survival, when combined chemotherapy and radiation therapy are given pre-operatively, are suggested by recent phase III trials. In fit patients, a significant survival benefit with pre-operative chemoradiation is seen in those patients who achieve a pathologic complete response. In esophageal/GEJ cancer, definitive chemoradiation is now considered in medically inoperable patients. In squamous cell carcinoma of the esophagus, surgery after primary chemoradiation is not clearly associated with an improved overall survival, however, local control may be better. In localized gastric/GEJ cancer, the integration of bevacizumab with pre-operative chemotherapy is being explored in large randomized studies, and with chemoradiotherapy in pilot trials. The addition of anti-epidermal growth factor receptor and anti-human epidermal growth factor receptor-2 antibody treatment to pre-operative chemoradiation continues to be explored. Early results show the integration of targeted therapy is feasible. Metabolic imaging can predict early response to pre-operative chemotherapy and biomarkers may further predict response to pre-operative chemo-targeted therapy. A multimodality approach to localized gastro-esophageal cancer has resulted in better outcomes. For T3 or node-positive disease, surgery alone is no longer considered appropriate and neo-adjuvant therapy is recommended. The future of neo-adjuvant strategies in this disease will involve the individualization of therapy with the integration of molecular signatures, targeted therapy, metabolic imaging and predictive biomarkers.
Ajani, J.A., Baker, J., Pisters, P.W., Ho, L., Mansfield, P.F., Feig, B.W. et al. (2002) CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: Results of a phase II study. Cancer94: 641-646.
2.
Ajani, J.A., Winter, K., Komaki, R., Kelsen, D.P., Minsky, B.D., Liao, Z. et al. (2008) Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: Rtog 0113. J Clin Oncol26: 4551-4556.
3.
Allum, W.H., Fogarty, P.J., Stenning, S.P., Langley, R.E. and Group, N.U.G.C.C.S. ( 2008) Long term results of the MRC OEO2 randomized trial of surgery with or without preoperative chemotherapy in resectable esophageal cancer. Gastrointestinal Cancer Symposium, Orlando, FL, USA, 25-25 January 2008: Abstract 9.
4.
Anderson, M.R., Harrison, R., Atherfold, P.A., Campbell, M.J., Darnton, S.J., Obszynska, J. et al. (2006) MET receptor signaling: A key effector in esophageal adenocarcinoma. Clin Cancer Res12: 5936-5943.
5.
Bang, Y., Chung, H., Xu, J., Lordick, F., Sawaki, A., Lipatov, O. et al. (2009) Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the Toga trial. Amercan Society of Clinical Oncology, Annual Proceedings, Orlando, FL, USA, 29 May-2 June 2009. Abstract: 4556.
6.
Bedenne, L., Michel, P., Bouche, O., Milan, C., Mariette, C., Conroy, T. et al. (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol25: 1160-1168.
7.
Berger, A.C., Farma, J., Scott, W.J., Freedman, G., Weiner, L., Cheng, J.D. et al. (2005) Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival . J Clin Oncol23: 4330-4337.
8.
Bertagnolli, M.M., Eagle, C.J., Zauber, A.G., Redston, M., Breazna, A., Kim, K. et al. (2009) Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial. Cancer Prev Res ( Phila Pa) 2: 310-321.
9.
Boige, V., Pignon, J., Saint-Aubert, B., Lasser, P., Conroy, T., Bouché, O. et al. (2007) Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC Accord07-FFCD 9703 trial. American Society of Clinical Oncology, Chicago, IL, USA, 1-5 June 2007. Abstract: 4510.
10.
Bonner, J.A., Harari, P.M., Giralt, J., Azarnia, N., Shin, D.M., Cohen, R.B. et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med354: 567-578.
11.
Boone, J., Ten Kate, F.J., Offerhaus, G.J., Van Diest, P.J., Rinkes, I.H. and Van Hillegersberg, R. ( 2008) mTOR in squamous cell carcinoma of the oesophagus: A potential target for molecular therapy?J Clin Pathol61: 909-913.
12.
Boonstra, J.J., Dinjens, W.N., Tilanus, H.W. and Koppert, L.B. ( 2007) Molecular biological challenges in the treatment of esophageal adenocarcinoma. Expert Rev Gastroenterol Hepatol1: 275-286.
13.
Bosset, J.F., Gignoux, M., Triboulet, J.P., Tiret, E., Mantion, G., Elias, D. et al. (1997) Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med337: 161-167.
14.
Brenner, B., Ilson, D.H., Minsky, B.D., Bains, M.S., Tong, W., Gonen, M. et al. (2004) Phase I trial of combined-modality therapy for localized esophageal cancer: Escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol22: 45-52.
15.
Brien, T.P., Odze, R.D., Sheehan, C.E., Mckenna, B.J. and Ross, J.S. ( 2000) HER-2/neu gene amplification by FISH predicts poor survival in Barrett’s esophagus-associated adenocarcinoma. Hum Pathol31: 35-39.
16.
Burmeister, B.H., Smithers, B.M., Gebski, V., Fitzgerald, L., Simes, R.J., Devitt, P. et al. (2005) Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. Lancet Oncol6: 659-668.
17.
Cappuzzo, F., Varella-Garcia, M., Shigematsu, H., Domenichini, I., Bartolini, S., Ceresoli, G.L. et al. (2005) Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol23: 5007-5018.
18.
Cooper, J.S., Guo, M.D., Herskovic, A., Macdonald, J.S., Martenson Jr, J.A., Al-Sarraf, M. et al. (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA281: 1623-1627.
19.
Corley, D.A., Kerlikowske, K., Verma, R. and Buffler, P. ( 2003) Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis. Gastroenterology124: 47-56.
20.
Cunningham, D., Allum, W.H., Stenning, S.P., Thompson, J.N., Van De Velde, C.J., Nicolson, M. et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med355: 11-20.
21.
Dannenberg, A.J., Lippman, S.M., Mann, J.R., Subbaramaiah, K. and Dubois, R.N. ( 2005) Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention. J Clin Oncol23: 254-266.
22.
Dawson, S.J., Michael, M., Biagi, J., Foo, K.F., Jefford, M., Ngan, S.Y. et al. (2007) A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs25: 123-129.
23.
Debucquoy, A., Haustermans, K., Daemen, A., Aydin, S., Libbrecht, L., Gevaert, O. et al. (2009) Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol27: 2751-2757.
24.
Dobelbower, M.C., Russo, S.M., Raisch, K.P., Seay, L.L., Clemons, L.K., Suter, S. et al. (2006) Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: A phase I study. Anticancer Drugs17: 95-102.
25.
Dragovich, T., McCoy, S., Fenoglio-Preiser, C.M., Wang, J., Benedetti, J.K., Baker, A.F. et al. (2006) Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol24: 4922-4927.
26.
Duhaylongsod, F.G., Gottfried, M.R., Iglehart, J.D., Vaughn, A.L. and Wolfe, W.G. ( 1995) The significance of C-ERB B-2 and P53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg221: 677-683.
27.
Enzinger, P.C., Fidias, P., Stuart, K. and Al, E. ( 2006) Phase II study of bevacizumab anddocetaxel (avatax) in metastatic esophageal and gastric cancer. Ann Oncol17: 1078PDa.
28.
Enzinger, P.C., Mamon, H., Choi, N., Bueno, R., Kulke, M.H., Fidias, P. et al. (2004) Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. American Society of Clinical Oncology, Chicago, IL, USA, 2004: Abstract 35.
29.
Enzinger, P.C., Ryan, D.P., Regan, E.M., Lehman, N., Abrams, T.A., Hezel, A.F. et al. (2008) Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. American Society of Clinial Oncology, Chicago, IL, USA: Abstract 4552.
30.
Enzinger, P.C., Yock, T., Suh, W., Fidias, P., Mamon, H., Choi, N. et al. (2006) Phase II cisplatin, irinotecan, cetuximab and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. American Society of Clinical Oncology, Orlando, FL, USA, 1-5 June 2006: Abstract 4064.
31.
Fareed, K.R., Kaye, P., Soomro, I.N., Ilyas, M., Martin, S., Parsons, S.L. et al. (2009) Biomarkers of response to therapy in oesophago-gastric cancer . Gut58: 127-143.
32.
Fiorica, F., Di Bona, D., Schepis, F., Licata, A., Shahied, L., Venturi, A. et al. (2004) Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and meta-analysis. Gut53: 925-930.
33.
Gebski, V., Burmeister, B., Smithers, B.M., Foo, K., Zalcberg, J. and Simes, J. ( 2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol8: 226-234.
34.
Gold, P.J., Goldman, B., Iqbal, S., Leichman, L.P., Lenz, H.J. and Blanke, C.D. ( 2008) Cetuximab as second-line therapy in patients with metastatic esophageal cancer: A phase II Southwest Oncology Group Study. Amercan Society of Clinical Oncology, Chigago, IL, USA: Abstract 4536.
35.
Govindan, R., Mcleod, H., Mantravadi, P., Fineberg, N., Helft, P., Kesler, K. et al. (2004) Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: Preliminary results. Oncology (Williston Park) 18: 18-21.
36.
Group, M.R.C.O.C.W. ( 2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet359: 1727-1733.
37.
Guo, M., Liu, S. and Lu, F. ( 2006) Gefitinib-sensitizing mutations in esophageal carcinoma . N Engl J Med354: 2193-2194.
38.
Harris, D.T. and Mastrangelo, M.J. ( 1991) Theory and application of early systemic therapy . Semin Oncol18: 493-503.
39.
Heath, E.I., Burtness, B.A., Kleinberg, L., Salem, R.R., Yang, S.C., Heitmiller, R.F. et al. (2006) Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (MMP) inhibitor prinomastat in patients with esophageal adenocarcinoma. Invest New Drugs24: 135-140.
40.
Hecht, J.R., Urba, S.G., Koehler, M., Ellis, C., Gagnon, R., Kemner, A. et al. (2008) Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: Phase II efficacy and biomarker analyses. Gastrointestinal Cancer Symposium, Orlando, FL, USA, 15-17 January 2008: Abstract 43.
41.
Herskovic, A., Martz, K., Al-Sarraf, M., Leichman, L., Brindle, J., Vaitkevicius, V. et al. (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med326: 1593-1598.
42.
Hildebrandt, M.A., Yang, H., Hung, M.C., Izzo, J.G., Huang, M., Lin, J. et al. (2009) Genetic variations in the PI3k/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol27: 857-871.
43.
Horgan, A.M., Darling, G., Wong, R., Liu , G., Jonker, D., Hornby, J. et al. (2009) Adjuvant sunitinib following chemoradiotherapy and surgery for esophageal cancer: A phase II trial. Gastrointestinal Cancer Symposium, Orlando, FL, USA, 15-17 January 2009: Abstract 109.
44.
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med350: 2335-2342.
45.
Ilson, D.H., Bains, M., Kelsen, D.P., O’Reilly, E., Karpeh, M., Coit, D. et al. (2003) Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol21: 2926-2932.
46.
Ilson, D.H., Bains, M., Rizk, N., Rusch, V., Flores, R., Park, B. et al. (2009a) Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (Rt) in esophageal adenocarcinoma: Preliminary safety analysis. American Society of Clinial Oncology, Annual Proceedings: Orlando, FL, USA: Abstract 4573.
47.
Ilson, D.H., Bains, M., Rizk, N., Rusch, V., Flores, R., Park, B. et al. (2009b) Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (Rt) in esophageal adenocarcinoma: Preliminary safety analysis. Gastrointestinal Cancer Symposium, Orlando, FL, USA, 15-17 January 2009: Abstract 79.
48.
Ilson, D.H., Saltz, L., Enzinger, P., Huang, Y., Kornblith, A., Gollub, M. et al. (1999) Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol17: 3270-3275.
49.
Iqbal, S., Goldman, B., Lenz, H.J., Fenoglio-Preiser, C.M. and Blanke, C.D. ( 2007) S0413: A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (Pts) with advanced or metastatic gastric cancer . American Society of Clinical Oncology, Chicago, IL, USA, 1-5 June 2007: Abstract 4621.
50.
Jankowski, J.A. and Odze, R.D.(2009) Biomarkers in gastroenterology: Between hope and hype comes histopathology . Am J Gastroenterol104: 1093-1096.
51.
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. et al. (2008) Cancer statistics, 2008. CA Cancer J Clin58: 71-96.
52.
Jhawer, M., Tse, A., Ilson, D.H., Robinson, E., Zheng, J., Randazzo, J. et al. (2009) Phase II study of modified docetaxel, cisplatin, fluorouracil (MDCF), and bevacizumab (Bev) in patients with metastatic gastroesophageal (Ge) adenocarcinoma. Gastrointestinal Cancer Symposium , San Francisco, CA, USA, 15-17 January 2009: Abstract 10.
53.
Jhawer, M.P., Kindler, H.L., Wainberg, Z.A., Hecht, J.R., Kerr, R.O., Ford, J.M. et al. (2008) Preliminary activity of Xl880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study. Amercan Society of Clinical Oncology, Chigago, IL, USA: Abstract 4572.
54.
Jouve, J., Michel, P., Mariette, C., Bonnetain, F., Bouché, O., Conroy, T. et al. (2008) Outcome of the nonrandomized patients in the FFCD 9102 trial: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus. Amercan Society of Clinical Oncology, Chigago, IL, USA: Abstract 4555.
55.
Kamangar, F., Dores, G.M. and Anderson, W.F. ( 2006) Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol24: 2137-2150.
56.
Kang, Y., Bang, Y., Lordick, F., Park, S., Sawaki, A., Chung, H. et al. (2008) Incidence of gastric and gastro-esophageal cancer in the Toga trial: Correlation with HER2 positivity. American Society of Clinical Oncology, Chicago, IL , USA, 1-5 June 2008: Abstract 11.
57.
Karamouzis, M.V., Grandis, J.R. and Argiris, A. ( 2007) Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. Jama298: 70-82.
58.
Karayiannakis, A.J., Syrigos, K.N., Polychronidis, A., Zbar, A., Kouraklis, G., Simopoulos, C. et al. (2002) Circulating VEGF levels in the serum of gastric cancer patients: Correlation with pathological variables, patient survival, and tumor surgery. Ann Surg236: 37-42.
59.
Kawaguchi, Y., Kono, K., Mimura, K., Sugai, H., Akaike, H. and Fujii, H. ( 2007) Cetuximab induced antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer120: 781-787.
60.
Kelsen, D.P., Ginsberg, R., Pajak, T.F., Sheahan, D.G., Gunderson, L., Mortimer, J. et al. (1998) Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med339: 1979-1984.
61.
Kelsen, D.P., Jhawer, M., Ilson, D.H., Tse, A., Randazzo, J., Robinson, E. et al. (2009) Analysis of survival with modified docetaxel, cisplatin, fluorouracil (MDCF), and bevacizumab (Bev) in patients with metastatic gastroesophageal (Ge) adenocarcinoma: Results of a phase II clinical trial . Amercan Society of Clinical Oncology, Annual Proceedings, Orlando, FL: Abstract #4512.
62.
Khushalani, N.I., Leichman, C.G., Proulx, G., Nava, H., Bodnar, L., Klippenstein, D. et al. (2002) Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: Report of a clinical trial for patients with esophageal cancer. J Clin Oncol20: 2844-2850.
63.
Kleespies, A., Guba, M., Jauch, K.W. and Bruns, C.J. ( 2004) Vascular endothelial growth factor in esophageal cancer . J Surg Oncol87: 95-104.
64.
Kleinberg, L., Powell, M.E., Forastiere, A., Keller, S., Anne, P. and Benson, A.B. ( 2007) E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/RT or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged adenocarcinoma of the esophagus . American Society of Clinical Oncology , Chicago, IL, USA, 1-5 June 2007 : Abstract 4533.
65.
Ku, G.Y., Bains, M., Rizk, N., Shah, M.A., Rusch, V., Capanu, M. et al. (2007) Phase II trial of pre-operative cisplatin/irinotecan and radiotherapy for locally advanced esophageal cancer: Pet scan after induction therapy may identify early treatment failure. Gastrointestinal Cancer Symposium, Orlando, FL, USA, 25-25 January 2007: Abstract 9.
66.
Ku, G.Y., Bains, M., Rizk, N., Shah, M.A., Rusch, V., Capanu, M. et al. (2008) Phase II trial of pre-operative cisplatin/irinotecan and radiotherapy for locally advanced esophageal cancer: pet scan after induction therapy may identify early treatment failure. Gastrointestinal Cancer Symposium, Orlando, FL, USA, 25-25 January 2007: Abstract 9.
67.
Kulke, M.H., Odze, R.D., Mueller, J.D., Wang, H., Redston, M. and Bertagnolli, M.M. ( 2004) Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg127: 1579-1586.
68.
Kwak, E.L., Jankowski, J., Thayer, S.P., Lauwers, G.Y., Brannigan, B.W., Harris, P.L. et al. (2006) Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res12: 4283-4287.
69.
Langer, C.J. ( 2004) Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: Focus on NSCLC. Int J Radiat Oncol Biol Phys58: 991-1002.
70.
Lee, J.L., Park, S.I., Kim, S.B., Jung, H.Y., Lee, G.H., Kim, J.H. et al. (2004) A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol15: 947-954.
71.
Lee, S.H., Lee, J.W., Soung, Y.H., Kim, H.S., Park, W.S., Kim, S.Y. et al. (2003) BRAFand KRAS mutations in stomach cancer. Oncogene22: 6942-6945.
72.
Leichman, L., Goldman, B.H., Benedetti, J.K., Billingsley, K.G., Thomas, C.R., Iqbal, S. et al. (2009) Oxaliplatin (Oxp) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to durgery (S) for potentially curable esophageal adenocarcinoma (Ea): A Southwest Oncology Group (SWOG) Phase II trial with molecular correlates (S0356). Amercan Society of Clinical Oncology, Annual Proceedings, Orlando, FL: Abstract #4513.
73.
Lievre, A., Bachet, J.B., Boige, V., Cayre, A., Le Corre, D., Buc, E. et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab . J Clin Oncol26: 374-379.
74.
Lordick, F., Ott, K., Krause, B.J., Weber, W.A., Becker, K., Stein, H.J. et al. (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The municon phase II trial. Lancet Oncol8: 797-805.
75.
Lorenzen, S., Brucher, B., Zimmermann, F., Geinitz, H., Riera, J., Schuster, T. et al. (2008) Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: Results of a phase I/II Trial. Br J Cancer99: 1020-1026.
76.
Lurje, G., Zhang, W., Yang, D., Groshen, S., Hendifar, A.E., Husain, H. et al. (2008) Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics18: 161-168.
77.
Luthra, M.G., Ajani, J.A., Izzo, J., Ensor, J., Wu, T.T., Rashid, A. et al. (2007) Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res13: 912-919.
78.
Luthra, R., Wu, T.T., Luthra, M.G., Izzo, J., Lopez-Alvarez, E., Zhang, L. et al. (2006) Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation . J Clin Oncol24: 259-267.
79.
Ma, H.Y., Ryan, T., Newman, E., Cohen, D.J., Choi, H. and Hochster, H.S. ( 2009) Neoadjuvant therapy of gastric cancer with irinotecan, cisplatin, and cetuximab followed by surgical resection and adjuvant chemoradiation . Gastrointestinal Cancer Symposium, Orlando, FL, USA, 15-17 January 2009: Abstract 58.
80.
Machiels, J.P., Sempoux, C., Scalliet, P., Coche, J.C., Humblet, Y., Van Cutsem, E. et al. (2007) Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer . Ann Oncol18: 738-744.
81.
Maeda, K., Chung, Y.S., Ogawa, Y., Takatsuka, S., Kang, S.M., Ogawa, M. et al. (1996) Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer77: 858-863.
82.
Matsubara, J., Nishina, T., Yamada, Y., Moriwaki, T., Shimoda, T., Kajiwara, T. et al. (2008) Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer98: 832-839.
83.
McDonnell, C.O., Bouchier-Hayes, D.J., Toomey, D., Foley, D., Kay, E.W., Leen, E. et al. (2003) Effect of neoadjuvant chemoradiotherapy on angiogenesis in oesophageal cancer. Br J Surg90: 1373-1378.
84.
Mimura, K., Kono, K., Hanawa, M., Kanzaki, M., Nakao, A., Ooi, A. et al. (2005) Trastuzumab-mediated antibody-dependent cellular cytotoxicity against Esophageal squamous cell carcinoma. Clin Cancer Res11: 4898-4904.
85.
Minsky, B.D., Pajak, T.F., Ginsberg, R.J., Pisansky, T.M., Martenson, J., Komaki, R. et al. (2002) Int 0123 (Radiation Therapy Oncology Group 94-05) Phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol20: 1167-1174.
86.
Mukaida, H., Toi, M., Hirai, T., Yamashita, Y. and Toge, T. ( 1991) Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer68: 142-148.
87.
Muro, K., Boku, N., Yamada, Y., Nishina, T., Doi, T., Takiuchi, H. et al. (2008) Multicenter phase II study of Rad001 for previously treated metastatic gastric cancer (MGC): Preliminary results. American Society of Clinial Oncology, Annual Proceedings, Chicago, IL, USA: Abstract 4541.
88.
O’Cconnor, B.M., Chadha, M.K., Pande, A., Lombardo, J.C., Nwogu, C.E., Nava, H.R. et al. (2007) Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma. Cancer J13: 119-124.
89.
Ocean, A.J., Schnoll-Sussman, F., Chen, X.E., Keresztes, R., Holloway, S., Matthews, N. et al. (2007) Recent results of phase II study of Ps-341 (bortezomib) with or without irinotecan in patients (Pts) with advanced gastric adenocarcinomas (AGA). Gastrointestinal Cancer Symposium, Orlando, FL, USA, 15-17 January 2007. Abstract:45.
90.
Olaussen, K.A., Dunant, A., Fouret, P., Brambilla, E., Andre, F., Haddad, V. et al. (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med355: 983-991.
91.
Pai, R., Soreghan, B., Szabo, I.L., Pavelka, M., Baatar, D. and Tarnawski, A.S. ( 2002) Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy . Nat Med8: 289-293.
92.
Parkin, D.M., Bray, F., Ferlay, J. and Pisani, P. ( 2005) Global cancer statistics, 2002. CA Cancer J Clin55: 74-108.
93.
Pegram, M.D., Lopez, A., Konecny, G. and Slamon, D.J. ( 2000) Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol27: 21-25.
94.
Pera, M., Cameron, A.J., Trastek, V.F., Carpenter, H.A. and Zinsmeister, A.R. ( 1993) Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology104: 510-513.
95.
Personeni, N. ( 2006) Epidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib: Does intratumoral heterogeneity matter? J Clin Oncol24: 5465.
96.
Pinto, C., Di Fabio, F., Siena, S., Cascinu, S., Rojas Llimpe, F.L., Ceccarelli, C. et al. (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (Folcetux Study). Ann Oncol18: 510-517.
97.
Raben, D., Helfrich, B. and Bunn Jr, P.A. ( 2004) Targeted therapies for non-small-cell lung vancer: Biology, rationale, and preclinical results from a radiation oncology perspective . Int J Radiat Oncol Biol Phys59: 27-38.
98.
Raisch, K.P., Russo, S.M., Seay, L.L., and Al., E. ( 2003) EGFR-specific tyrosine kinase inhibitor, erlotinib, in combination with ionizing radiation for the treatment of esophageal carcinoma cells. Presented at: International Conference on Molecular targets and Cancer Therapeutics Boston.
99.
Reynolds, J.V., Muldoon, C., Hollywood, D., Ravi, N., Rowley, S., O’Byrne, K. et al. (2007) Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg245: 707-716.
100.
Riely, G.J., Pao, W., Pham, D., Li, A.R., Rizvi, N., Venkatraman, E.S. et al. (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor Exon 19 and Exon 21 mutations treated with gefitinib or Erlotinib. Clin Cancer Res12: 839-844.
101.
Rodel, C., Arnold, D., Hipp, M., Liersch, T., Dellas, K., Iesalnieks, I. et al. (2008) Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys70: 1081-1086.
102.
Roof, K.S., Coen, J., Lynch, T.J., Wright, C., Fidias, P., Willett, C.G. et al. (2006) Concurrent cisplatin, 5-Fu, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys65: 1120-1128.
103.
Ruhstaller, T., Widmer, L., Schuller, J.C., Roth, A., Hess, V., Mingrone, W. et al. (2009) Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (Sakk 75/02). Ann Oncol22: 22.
104.
Safran, H., Dipetrillo, T., Akerman, P., Ng, T., Evans, D., Steinhoff, M. et al. (2007) Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys67: 405-409.
105.
Safran, H., Gaissert, H., Akerman, P., Hesketh, P.J., Chen, M.H., Moore, T. et al. (2001) Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest19: 1-7.
106.
Safran, H., Suntharalingam, M., Dipetrillo, T., Ng, T., Doyle, L.A., Krasna, M. et al. (2008) Cetuximab with concurrent chemoradiation for esophagogastric cancer: Assessment of toxicity. Int J Radiat Oncol Biol Phys70: 391-395.
107.
Sato, S., Kajiyama, Y., Sugano, M., Iwanuma, Y., Sonoue, H., Matsumoto, T. et al. (2005) Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/ neu oncoprotein . Int J Radiat Oncol Biol Phys61: 203-211.
108.
Schuhmacher, C., Schlag, P., Lordick, F., Hohenberger, W., Heise, J., Haag, C. et al. (2009) Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954. Amercan Society of Clinical Oncology, Annual Proceedings, Orlando, FL: Abstract #4510.
109.
Schuller, J.C., Balmer-Majno, S., Mingrone, W., Hess, V., Von Moos, R., Borner, M. et al. (2008) Preoperative induction chemotherapy with docetaxel-cisplatin followed by concurrent docetaxel-cisplatin and radiation therapy (Rt) in patients with locally advanced esophageal cancer: Final results of the multicenter phase Ll trial sakk 75/02. American Society of Clinical Oncology, Chicago, IL, USA, 30 May-3 June 2008: Abstract 4550.
110.
Sgroi, M.M., Hanna, N.H., Mccollum, A.D., Bechar, N., Dimaio, M., Hammoud, Z. et al. (2008) Preoperative cetuximab and radiation (Xrt) for patients (Pts) with surgically resectable esophageal and gastroesophageal (Ge) junction carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas-Southwestern. American Society of Clinical Oncology, Chicago, IL, USA, 1-5 June 2008: Abstract 4564.
111.
Shah, M.A., Ramanathan, R.K., Ilson, D.H., Levnor, A., D’adamo, D., O’Reilly, E. et al. (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol24: 5201-5206.
112.
Shimada, H., Matsubara, H., Shiratori, T., Shimizu, T., Miyazaki, S., Okazumi, S. et al. (2006) Phase I/II adenoviral P53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci97: 554-561.
113.
Slesak, B., Harlozinska, A., Porebska, I., Bojarowski, T., Lapinska, J., Rzeszutko, M. et al. (1998) Expression of epidermal growth factor receptor family proteins (EGFR, C-ERBB-2 and C-ERBB-3) in gastric cancer and chronic gastritis. Anticancer Res18: 2727-2732.
114.
Stahl, M., Stuschke, M., Lehmann, N., Meyer, H.J., Walz, M.K., Seeber, S. et al. (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol23: 2310-2317.
115.
Stahl, M., Walz, M.K., Stuschke, M., Lehmann, N., Meyer, H.J., Riera-Knorrenschild, J. et al. (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol27: 851-856.
116.
Stahl, M., Wilke, H., Lehmann, N., Stuschke, M. and Group, G.O.C.S. ( 2008) Long-term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous cell carcinoma (LA-SCC) of the esophagus. American Society of Clinial Oncology, Annual Proceedings, Chicago, IL, USA: Abstract 4530.
117.
Sun, W., Powell, M.E., O’Dwyer, P., Ansari, R.H. and Benson, A.B. ( 2008) A phase II study: Combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203). American Society of Clinical Oncology, Chicago, IL : USA: 1-5 June 2008: Abstract 4535.
118.
Tepper, J., Krasna, M.J., Niedzwiecki, D., Hollis, D., Reed, C.E., Goldberg, R. et al. (2008) Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol26: 1086-1092.
119.
Tew, W.P., Shah, M.A., Schwartz, G., Kelsen, D.P. and Ilson, D.H. ( 2005) Phase II trial of erlotonib for second-line treatment in advanced esophageal cancer. American Society of Clinical Oncology, Gastrointestinal Cancer Symposium: Abstract 5.
120.
Thirion, P.G., Michiels, S., Le Maître, A., Tierney, J. and Group, O.B.O.T.M.O.C.I.E.C.C. ( 2007) Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma. American Society of Clinical Oncology, Chicago, IL , USA, 1-5 June 2007: Abstract 4512.
121.
Tuynman, J.B., Buskens, C.J., Kemper, K., Ten Kate, F.J., Offerhaus, G.J., Richel, D.J. et al. (2005) Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann Surg242: 840-849.
122.
Tuynman, J.B., Lagarde, S.M., Ten Kate, F.J., Richel, D.J. and Van Lanschot, J.J. ( 2008) MET expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer98: 1102-1108.
123.
Urba, S.G., Orringer, M.B., Turrisi, A., Iannettoni, M., Forastiere, A. and Strawderman, M. ( 2001) Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol19: 305-313.
124.
Van Cutsem, E., Kang, K., Chung, H., Shen, L., Sawaki, A., Lordick, F. et al. (2009) Efficacy results from the Toga trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). American Society of Clinial Oncology, Annual Proceedings, Orlando, FL, USA, May 29-June 2: Abstract #LBA 4509.
125.
Van Cutsem, E., Kohne, C.H., Hitre, E., Zaluski, J., Chang Chien, C.R., Makhson, A. et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med360: 1408-1417.
126.
Van Cutsem, E., Moiseyenko, V.M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C. et al. (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group. J Clin Oncol24: 4991-4997.
127.
Van Cutsem, E., Van De Velde, C., Roth, A., Lordick, F., Kohne, C.H., Cascinu, S. et al. (2008) Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-Gastrointestinal Cancer Group . Eur J Cancer44: 182-194.
128.
Walsh, T.N., Noonan, N., Hollywood, D., Kelly, A., Keeling, N. and Hennessy, T.P. ( 1996) A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med335: 462-467.
129.
Xi, H., Baldus, S.E., Warnecke-Eberz, U., Brabender, J., Neiss, S., Metzger, R. et al. (2005) High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res11: 8341-8347.
130.
Yamashita, K., Mori, M., Kataoka, A., Inoue, H. and Sugimachi, K. ( 2001) The clinical significance of MMP-1 expression in oesophageal carcinoma. Br J Cancer84: 276-282.
